Emergent BioSolutions Inc. (EBS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 700M 1.4B 2.1B Q3 '21: 1.7B Q4 '21: 1.8B Q1 '22: 1.8B Q2 '22: 1.6B Q3 '22: 1.5B Q4 '22: 1.1B Q1 '23: 977M Q2 '23: 1.1B Q3 '23: 1.1B Q4 '23: 1B Q1 '24: 1.2B Q2 '24: 1.1B Q3 '24: 1.1B Q4 '24: 1B Q1 '25: 965.4M Q2 '25: 851.6M Q3 '25: 788.9M Q4 '25: 742.9M Q1 '26: 676.8M Q2 '26: 770.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

-350M 0 350M 700M 1.1B Q1 '18: 99.9M Q2 '18: 158.2M Q3 '18: 131.7M Q4 '18: 89.8M Q1 '19: 71.9M Q2 '19: -1.9M Q3 '19: 47.5M Q4 '19: 114.1M Q4 '21: 891.3M Q1 '22: 810.9M Q2 '22: 732.2M Q3 '22: 712.9M Q4 '22: 385.5M Q1 '23: 248.4M Q2 '23: 323.5M Q3 '23: 335.4M Q4 '23: 317.6M Q1 '24: 460.5M Q2 '24: 271.8M Q3 '24: 345.8M Q2 '18 Q1 '19 Q4 '19 Q2 '22 Q1 '23 Q4 '23 Q3 '24

Operating Income TTM

-900M -600M -300M 0 300M 600M 900M Q4 '20: 433.8M Q1 '21: 540.8M Q2 '21: 429.3M Q3 '21: 333.3M Q4 '21: 362M Q1 '22: 273.5M Q2 '22: 182.7M Q3 '22: 172.1M Q4 '22: -170M Q1 '23: -324.5M Q2 '23: -541.1M Q3 '23: -737.9M Q4 '23: -726.4M Q1 '24: -539M Q2 '24: -449.6M Q3 '24: -143M Q4 '24: -108.7M Q1 '25: -98.6M Q2 '25: 106.5M Q3 '25: 118.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Net Income TTM

-900M -600M -300M 0 300M 600M 900M Q3 '21: 227M Q4 '21: 234.7M Q1 '22: 160.4M Q2 '22: 102.9M Q3 '22: 48.5M Q4 '22: -211.6M Q1 '23: -393.2M Q2 '23: -601.7M Q3 '23: -778M Q4 '23: -760.5M Q1 '24: -565.3M Q2 '24: -587M Q3 '24: -208.8M Q4 '24: -190.6M Q1 '25: -131.6M Q2 '25: 139.5M Q3 '25: 75.9M Q4 '25: 52.6M Q1 '26: -8.6M Q2 '26: -176.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 300M 600M 900M Q2 '20: 447.5M Q3 '20: 488.5M Q4 '20: 537M Q1 '21: 559.4M Q2 '21: 657.4M Q4 '22: 693.4M Q1 '23: 690.4M Q2 '23: 711.2M Q3 '23: 740.8M Q4 '23: 705.4M Q1 '24: 697.1M Q2 '24: 802.6M Q3 '24: 748.4M Q4 '24: 681.3M Q1 '25: 625.2M Q2 '25: 396M Q3 '25: 359.3M Q4 '25: 326.2M Q1 '26: 309.7M Q2 '26: 339.9M Q3 '20 Q2 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-300M -150M 0 150M 300M 450M Q3 '21: 238.1M Q4 '21: 320.2M Q1 '22: 277.8M Q2 '22: 291.9M Q3 '22: 201.2M Q4 '22: -34.1M Q1 '23: -180.8M Q2 '23: -279.6M Q3 '23: -145.6M Q4 '23: -206.3M Q1 '24: -84.9M Q2 '24: 77M Q3 '24: 170.7M Q4 '24: 58.7M Q1 '25: 110.1M Q2 '25: 169M Q3 '25: 13M Q4 '25: 170.6M Q1 '26: 148M Q2 '26: 97.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: 22.9M Q4 '21: 96.1M Q1 '22: 77.6M Q2 '22: 126.6M Q3 '22: 63.2M Q4 '22: -149.9M Q1 '23: -279.5M Q2 '23: -358.7M Q3 '23: -209.4M Q4 '23: -257.9M Q1 '24: -132.2M Q2 '24: 37.6M Q3 '24: 138.1M Q4 '24: 35.8M Q1 '25: 94.4M Q2 '25: 155M Q3 '25: 1.4M Q4 '25: 156.8M Q1 '26: 135.4M Q2 '26: 85.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 52M Q2 '20: 53.5M Q3 '20: 54.3M Q1 '21: 54.5M Q2 '21: 54M Q3 '21: 53.7M Q1 '22: 50.7M Q2 '22: 50M Q3 '22: 49.9M Q1 '23: 50.2M Q2 '23: 50.7M Q3 '23: 51.8M Q1 '24: 52.2M Q2 '24: 52.6M Q3 '24: 55.6M Q1 '25: 57.3M Q2 '25: 54.2M Q3 '25: 56.5M Q1 '26: 56.5M Q2 '26: 51.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q3 '21: 4.20 Q4 '21: 4.36 Q1 '22: 2.99 Q2 '22: 1.84 Q3 '22: 0.70 Q4 '22: -4.24 Q1 '23: -7.86 Q2 '23: -11.96 Q3 '23: -15.29 Q4 '23: -14.83 Q1 '24: -10.95 Q2 '24: -11.17 Q3 '24: -4.03 Q4 '24: -3.60 Q1 '25: -2.58 Q2 '25: 2.58 Q3 '25: 1.43 Q4 '25: 0.93 Q1 '26: -0.19 Q2 '26: -3.46 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.